News
Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback